Novo Nordisk A/S is the sixth pharmaceutical manufacturer in recent months to announce restrictions on the discounts it provides to 340B contract pharmacies as the US Health and Human Services Department continues to review the situation.
Novo follows Eli Lilly and Company, AstraZeneca PLC, Sanofi, Novartis AG and United Therapeutics Corporation...







